GIM
GNOM icon

Glenmede Investment Management’s Global X Genomics & Biotechnology ETF GNOM Stock Holding History

Glenmede Investment Management’s Portfolio GNOM Stock Details GNOM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$24.3K Hold
625
– – ﹤0.01% 1388
2025
Q2 		$21.1K Buy
+625
New +$19.8K ﹤0.01% 1420

Other funds holding GNOM

FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
OAM
Oppenheimer Asset Management New York $8.76B AUM 23.12% 1-Year Est. Return
IWM
IHT Wealth Management Chicago, Illinois $4.3B AUM 21.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
IA
Insight Advisors Newtown, Pennsylvania $525M AUM 15.94% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return
CFD
Creative Financial Designs Kokomo, Indiana $1.65B AUM 15.6% 1-Year Est. Return

Glenmede Investment Management's GNOM Position: Q3 2025 in Review

Glenmede Investment Management held its Global X Genomics & Biotechnology ETF (GNOM) position steady in Q3 2025 at 625 shares worth $24.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1388.

Glenmede Investment Management first reported a position in GNOM in Q2 2025 and has held it in 2 quarters since. 41 funds tracked by Wall St. Rank hold GNOM as of Q3 2025.

  • Glenmede Investment Management held 625 shares of Global X Genomics & Biotechnology ETF worth $24.3K as of Q3 2025.
  • Glenmede Investment Management left its Global X Genomics & Biotechnology ETF share count unchanged in Q3 2025.
  • Global X Genomics & Biotechnology ETF made up ﹤0.01% of Glenmede Investment Management's portfolio in Q3 2025, its #1388 holding.
  • Glenmede Investment Management first reported a position in Global X Genomics & Biotechnology ETF in Q2 2025 and has held it in 2 quarters since.
  • 41 funds tracked by Wall St. Rank held Global X Genomics & Biotechnology ETF as of Q3 2025.

Based on Glenmede Investment Management's 13F filing for Q3 2025, filed 13 Nov 2025.